Will SoundHound AI Stock Recover?
SoundHound AI (NASDAQ:SOUN) is a leading maker of artificial intelligence…
Sell
18
NVNO Quote, Financials, Valuation and Earnings
Last price:
$2.72
Seasonality move
:
-18.69%
Day range:
$2.70 - $2.85
52-week range:
$2.45 - $6.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
252.46x
P/B ratio:
1.14x
Volume:
68.5K
Avg. volume:
89.6K
1-year change:
-49.45%
Market cap:
$48.2M
Revenue:
--
EPS (TTM):
-$1.27
Analysts' Opinion
-
Consensus RatingenVVeno Medical has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.50, enVVeno Medical has an estimated upside of 500% from its current price of $2.75.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.50 representing 100% downside risk from its current price of $2.75.
Fair Value
-
According to the consensus of 1 analyst, enVVeno Medical has 500% upside to fair value with a price target of $16.50 per share.
NVNO vs. S&P 500
-
Over the past 5 trading days, enVVeno Medical has underperformed the S&P 500 by -6.29% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
enVVeno Medical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
enVVeno Medical has grown year-over-year revenues for 1 quarter straight. In the most recent quarter enVVeno Medical reported revenues of --.
Earnings Growth
-
enVVeno Medical has grown year-over-year earnings for 0 quarters straight. In the most recent quarter enVVeno Medical reported earnings per share of -$0.30.
Enterprise value:
5.1M
EV / Invested capital:
--
Price / LTM sales:
252.46x
EV / EBIT:
--
EV / Revenue:
27.16x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-0.30x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$24.9M | -$25.2M | -$23.8M | -$6.3M | -$6.7M | |
| EBITDA | -$24.4M | -$24.7M | -$23.3M | -$6.1M | -$6.6M | |
| Diluted EPS | -$2.19 | -$1.92 | -$1.27 | -$0.32 | -$0.30 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $9.6M | $55M | $39.4M | $46.9M | $43.7M | |
| Total Assets | $10.5M | $57.7M | $41.7M | $48.6M | $45M | |
| Current Liabilities | $3.2M | $1.6M | $1.5M | $1.4M | $2.1M | |
| Total Liabilities | $3.4M | $3.3M | $2.9M | $2.4M | $2.8M | |
| Total Equity | $7.1M | $54.4M | $38.7M | $46.2M | $42.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$15.6M | -$18.9M | -$16.8M | -$5M | -$5.1M | |
| Cash From Investing | -$34.6M | -$7.9M | $1.3M | -$22.1M | -$11.1M | |
| Cash From Financing | -- | $25.8M | $13.6M | $25.8M | -- | |
| Free Cash Flow | -$15.7M | -$18.9M | -$16.9M | -$5M | -$5.1M | |
NVNO
Sector
Market Cap
$48.2M
$36.5M
Price % of 52-Week High
42.44%
44.66%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.9%
1-Year Price Total Return
-49.45%
-39.9%
Beta (5-Year)
1.377
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.89
200-day SMA
Sell
Level
$3.99
Bollinger Bands (100)
Sell
Level
2.91 - 3.45
Chaikin Money Flow
Sell
Level
-44.6M
20-day SMA
Sell
Level
$2.93
Relative Strength Index (RSI14)
Sell
Level
37.90
ADX Line
Sell
Level
14.36
Williams %R
Buy
Level
-86.1111
50-day SMA
Sell
Level
$3.18
MACD (12, 26)
Sell
Level
-0.11
25-day Aroon Oscillator
Sell
Level
-4
On Balance Volume
Neutral
Level
80.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.
Stock Forecast FAQ
In the current month, NVNO has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NVNO average analyst price target in the past 3 months is $16.50.
-
Where Will enVVeno Medical Stock Be In 1 Year?
According to analysts, the consensus estimate is that enVVeno Medical share price will rise to $16.50 per share over the next 12 months.
-
What Do Analysts Say About enVVeno Medical?
Analysts are divided on their view about enVVeno Medical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that enVVeno Medical is a Sell and believe this share price will drop from its current level to $16.50.
-
What Is enVVeno Medical's Price Target?
The price target for enVVeno Medical over the next 1-year time period is forecast to be $16.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NVNO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for enVVeno Medical is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of NVNO?
You can purchase shares of enVVeno Medical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase enVVeno Medical shares.
-
What Is The enVVeno Medical Share Price Today?
enVVeno Medical was last trading at $2.72 per share. This represents the most recent stock quote for enVVeno Medical. Yesterday, enVVeno Medical closed at $2.75 per share.
-
How To Buy enVVeno Medical Stock Online?
In order to purchase enVVeno Medical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Stocks Did Warren Buffett Just Buy?
In Q4 of last year, Warren Buffett added to or…
Is it Finally Time to Buy Medical Properties Trust?
Medical Properties Trust (NYSE:MPW) is a REIT that focuses on…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 29
Ajinomoto [AJINY] is up 99.61% over the past day.
Buy
69
AGX alert for Mar 29
Argan [AGX] is up 19.83% over the past day.
Sell
24
AIR alert for Mar 29
AAR [AIR] is down 16.36% over the past day.
